Select publications

Publications discussed by Dr Gnant

Gnant M. Impact of participation in randomized clinical trials on survival of women with earlystage breast cancer – An analysis of 7,985 patients. Proc ASCO 2000:Abstract 287.

Gnant M et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. Breast Cancer Res Treat 2002;Abstract 12.

Jakesz R et al. Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group. Ann Surg 2003:237(4):556-64. Abstract

Adjuvant chemotherapy versus endocrine treatment in premenopausal, hormone receptor-positive breast cancer

Aapro MS. Adjuvant therapy of primary breast cancer: A review of key findings from the 7th international conference, St Gallen, February 2001. Oncologist 2001;6(4):376-85. Abstract

Abrams JS. Adjuvant therapy for breast cancer — results from the USA consensus conference. Breast Cancer 2001;8(4):298-304. Abstract

Andersson M et al. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial. Eur J Cancer 1999;35(12):1659-66. Abstract

Boccardo F et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18(14):2718-27. Abstract

Davidson N et al. Effect of chemohormonal therapy in pre-menopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group Phase III Intergroup trial (E5188, INT-0101). Proc ASCO 1999;Abstract 249A, 67A.

Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 2000;CD000485. Abstract

Ejlertsen B et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc ASCO 1999:Abstract.

Jakesz R. Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proc ASCO 1999;Abstract 250.

Jakesz R et al. Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer. Eur J Cancer 2002;38(3):327-32. Abstract

Jakesz R et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20(24):4621-7. Abstract

Jonat W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002 Dec 15;20(24):4628-35. Abstract

Jonat W. Zoladex vs. CMF as adjuvant therapy in pre-/perimenopausal early (node positive) breast cancer: Preliminary efficacy, QOL and BMD results from the ZEBRA study. Breast Cancer Res Treat 2000:No abstract available.

Kaufman M et al. Updated survival results from the ZEBRA trial. Breast Cancer Res Treat 2002;Abstract 254.

Roche HH et al. Complete hormonal blockage versus chemotherapy in premenopausal early-stage breast cancer patients with positive hormone-receptor and 1-3 node-positive tumor, results of the FASG 06 trial. Proc ASCO 2000. No abstract available

Sauerbrei W et al. Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: An update based on 10 years' follow-up. German Breast Cancer Study Group. J Clin Oncol 2000;18(1):94-101. Abstract

Schmid P et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res 2002;22(4):2325-32. Abstract

Vorgias G et al. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen. Anticancer Res 2000;20(5C):3849-54. Abstract

Home · Search